The objective of this study was to confirm if two formulations of alprazolam (tablets) are
Test product was Zamoprax® 2 mg (GlaxoSmithKline) and reference product Tafil® 2 mg
(Pharmacia & Upjohn). One tablet was the single dosage.
The study was prospective, open-label, randomized, crossover, single dose, with 02
treatments, 02 sequences and 02 periods, under fasting conditions.
The population was composed of 26 healthy volunteers, both genders, adults between 18-50
The comparative bioavailability of the two formulations was evaluated based in statistical
comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations